vs

Side-by-side financial comparison of Anterix Inc. (ATEX) and China SXT Pharmaceuticals, Inc. (SXTC). Click either name above to swap in a different company.

Anterix Inc. is the larger business by last-quarter revenue ($1.6M vs $829.5K, roughly 1.9× China SXT Pharmaceuticals, Inc.). China SXT Pharmaceuticals, Inc. runs the higher net margin — -96.8% vs -419.6%, a 322.9% gap on every dollar of revenue. On growth, Anterix Inc. posted the faster year-over-year revenue change (0.4% vs 0.0%). China SXT Pharmaceuticals, Inc. produced more free cash flow last quarter ($-1.8M vs $-8.3M).

Anterix Inc. is a U.S.-headquartered wireless communications company that owns licensed 900 MHz spectrum assets, providing secure, dedicated private broadband network solutions for critical infrastructure operators including electric utilities, public safety agencies, and transportation providers. Its primary market is North America, supporting clients requiring highly reliable connectivity for mission-critical operations.

China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the Chinese domestic market. It engages in the research, development, production and distribution of traditional Chinese medicine-based prescription drugs, over-the-counter medications, and nutritional health products, serving both clinical medical institutions and consumer health markets.

ATEX vs SXTC — Head-to-Head

Bigger by revenue
ATEX
ATEX
1.9× larger
ATEX
$1.6M
$829.5K
SXTC
Growing faster (revenue YoY)
ATEX
ATEX
+0.4% gap
ATEX
0.4%
0.0%
SXTC
Higher net margin
SXTC
SXTC
322.9% more per $
SXTC
-96.8%
-419.6%
ATEX
More free cash flow
SXTC
SXTC
$6.5M more FCF
SXTC
$-1.8M
$-8.3M
ATEX

Income Statement — Q3 FY2026 vs Q2 FY2026

Metric
ATEX
ATEX
SXTC
SXTC
Revenue
$1.6M
$829.5K
Net Profit
$-6.6M
$-802.6K
Gross Margin
16.2%
Operating Margin
-576.0%
-76.9%
Net Margin
-419.6%
-96.8%
Revenue YoY
0.4%
0.0%
Net Profit YoY
-185.6%
0.0%
EPS (diluted)
$-0.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATEX
ATEX
SXTC
SXTC
Q4 25
$1.6M
Q3 25
$1.6M
$829.5K
Q2 25
$1.4M
Q1 25
$1.4M
Q4 24
$1.6M
Q3 24
$1.6M
$829.5K
Q2 24
$1.5M
Q1 24
$1.3M
Net Profit
ATEX
ATEX
SXTC
SXTC
Q4 25
$-6.6M
Q3 25
$53.5M
$-802.6K
Q2 25
$25.2M
Q1 25
$9.2M
Q4 24
$7.7M
Q3 24
$-12.8M
$-802.6K
Q2 24
$-15.5M
Q1 24
$-9.4M
Gross Margin
ATEX
ATEX
SXTC
SXTC
Q4 25
Q3 25
16.2%
Q2 25
Q1 25
Q4 24
Q3 24
16.2%
Q2 24
Q1 24
Operating Margin
ATEX
ATEX
SXTC
SXTC
Q4 25
-576.0%
Q3 25
-76.9%
Q2 25
Q1 25
Q4 24
Q3 24
-846.6%
-76.9%
Q2 24
-984.4%
Q1 24
-834.2%
Net Margin
ATEX
ATEX
SXTC
SXTC
Q4 25
-419.6%
Q3 25
3449.5%
-96.8%
Q2 25
1775.7%
Q1 25
662.9%
Q4 24
492.3%
Q3 24
-823.1%
-96.8%
Q2 24
-1018.0%
Q1 24
-746.9%
EPS (diluted)
ATEX
ATEX
SXTC
SXTC
Q4 25
$-0.35
Q3 25
$2.86
Q2 25
$1.35
Q1 25
$0.51
Q4 24
$0.41
Q3 24
$-0.69
$-0.25
Q2 24
$-0.84
Q1 24
$-0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATEX
ATEX
SXTC
SXTC
Cash + ST InvestmentsLiquidity on hand
$29.5M
$18.1M
Total DebtLower is stronger
$105.0K
Stockholders' EquityBook value
$236.0M
$15.4M
Total Assets
$417.0M
$21.7M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATEX
ATEX
SXTC
SXTC
Q4 25
$29.5M
Q3 25
$39.1M
$18.1M
Q2 25
$41.4M
Q1 25
$47.4M
Q4 24
$28.8M
Q3 24
$43.1M
$18.5M
Q2 24
$51.7M
Q1 24
$60.6M
Total Debt
ATEX
ATEX
SXTC
SXTC
Q4 25
Q3 25
$105.0K
Q2 25
Q1 25
Q4 24
Q3 24
$952.3K
Q2 24
Q1 24
Stockholders' Equity
ATEX
ATEX
SXTC
SXTC
Q4 25
$236.0M
Q3 25
$240.3M
$15.4M
Q2 25
$184.8M
Q1 25
$156.6M
Q4 24
$144.7M
Q3 24
$139.1M
$15.0M
Q2 24
$148.8M
Q1 24
$161.0M
Total Assets
ATEX
ATEX
SXTC
SXTC
Q4 25
$417.0M
Q3 25
$420.4M
$21.7M
Q2 25
$359.6M
Q1 25
$333.1M
Q4 24
$326.7M
Q3 24
$317.2M
$31.0M
Q2 24
$321.1M
Q1 24
$324.9M
Debt / Equity
ATEX
ATEX
SXTC
SXTC
Q4 25
Q3 25
0.01×
Q2 25
Q1 25
Q4 24
Q3 24
0.06×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATEX
ATEX
SXTC
SXTC
Operating Cash FlowLast quarter
$-8.3M
$-1.4M
Free Cash FlowOCF − Capex
$-8.3M
$-1.8M
FCF MarginFCF / Revenue
-526.4%
-216.2%
Capex IntensityCapex / Revenue
0.6%
4.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATEX
ATEX
SXTC
SXTC
Q4 25
$-8.3M
Q3 25
$1.4M
$-1.4M
Q2 25
$-3.1M
Q1 25
$-16.6M
Q4 24
$-7.7M
Q3 24
$-2.6M
$-1.4M
Q2 24
$-2.4M
Q1 24
$6.1M
Free Cash Flow
ATEX
ATEX
SXTC
SXTC
Q4 25
$-8.3M
Q3 25
$-1.8M
Q2 25
Q1 25
$-16.6M
Q4 24
Q3 24
$-2.7M
Q2 24
Q1 24
$6.1M
FCF Margin
ATEX
ATEX
SXTC
SXTC
Q4 25
-526.4%
Q3 25
-216.2%
Q2 25
Q1 25
-1195.2%
Q4 24
Q3 24
-173.4%
Q2 24
Q1 24
484.1%
Capex Intensity
ATEX
ATEX
SXTC
SXTC
Q4 25
0.6%
Q3 25
4.9%
Q2 25
Q1 25
3.3%
Q4 24
0.0%
Q3 24
2.6%
Q2 24
0.0%
Q1 24
3.2%
Cash Conversion
ATEX
ATEX
SXTC
SXTC
Q4 25
Q3 25
0.03×
Q2 25
-0.12×
Q1 25
-1.80×
Q4 24
-1.00×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons